Aditxt, Inc. (NASDAQ:ADTX) Short Interest Up 201.6% in June

Aditxt, Inc. (NASDAQ:ADTX) was the target of a significant increase in short interest in June. As of June 15th, there was short interest totaling 281,498 shares, an increase of 201.6% from the May 31st total of 93,339 shares. Currently, 34.5% of the company’s stock are short sold. Based on an average trading volume of 321,156,604 shares, the days-to-cover ratio is currently 0.0 days.

Aditxt Trading Down 8.7%

Shares of NASDAQ:ADTX traded down $0.00 during mid-day trading on Friday, hitting $0.00. 135,771,321 shares of the company traded hands, compared to its average volume of 126,282,914. The stock has a 50-day moving average price of $2.43 and a two-hundred day moving average price of $103.94. Aditxt has a 12-month low of $0.00 and a 12-month high of $37,344.24. The stock has a market cap of $1,713.60, a P/E ratio of -0.00 and a beta of 0.84.

Aditxt (NASDAQ:ADTX) last released its quarterly earnings results on Tuesday, March 31st. The company reported $315,563.31 EPS for the quarter. Aditxt had a negative return on equity of 374.60% and a negative net margin of 360,152.50%.

Insider Transactions at Aditxt

In other Aditxt news, major shareholder Financial Lp Hrt sold 3,132,480 shares of the firm’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $0.01, for a total value of $31,324.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 3,260,940 shares of company stock worth $45,518 over the last 90 days. 0.01% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ADTX. Weiss Ratings cut Aditxt from a “sell (e+)” rating to a “sell (e)” rating in a report on Wednesday. Wall Street Zen raised shares of Aditxt to a “sell” rating in a research note on Saturday, May 23rd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Aditxt Company Profile

Aditxt, Inc is a clinical-stage biotechnology company focused on the development and commercialization of natural antimicrobial peptides and microbiome-based detection technologies. Leveraging proprietary peptide libraries, the company aims to provide novel solutions for infection prevention and control across healthcare, food safety, animal health and agricultural markets. Aditxt’s approach centers on harnessing peptides that can disrupt microbial cell membranes without promoting resistance, addressing a growing need for alternatives to traditional antibiotics and chemical disinfectants.

The company’s product offerings include contract-based microbial detection and identification services, designed to help hospitals, food processors and other regulated industries monitor contamination levels and validate hygiene protocols.